In this analysis, the role of metabolic imaging with fluorine 18 fluorodeoxyglucose (FDG) in breast cancer is reviewed. The analysis was limited to recent works by using state-ofthe-art positron emission tomography (PET)/computed tomography ( 
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Groheux et al along the glycolysis pathway and remains trapped within cancer cells. Modern whole-body PET systems typically have a reconstructed spatial resolution of 5-6 mm full width at half maximum, on the basis of phantom measurements. In clinical practice, however, reconstructed resolution is close to 10 mm. Small tumor foci and micrometastases cannot therefore be detected. However, detection depends not only on tumor size but also on the degree of FDG avidity, tumor-to-background ratio, effect of motion (respiration), et cetera. A smaller than 1 cm lesion can be detected when conditions are favorable.
Tumor FDG uptake can be expressed by using a so-called standardized uptake value (SUV). This index reflects the degree of FDG uptake within a volume of interest. It is calculated on the basis of the amount of activity injected and the patient's body mass, as follows: SUV = A mea /(A inj /W), where A mea is the measured activity in the volume of interest in kilobecquerels per milliliter, A inj is the injected activity in kilobecquerels, and W is the body weight of the patient in grams (6) .
There are many other ways to measure FDG uptake, as well as other expressions for SUVs with calculations that are based on body surface area or lean body mass or with use of modifiers (eg, correction for blood glucose level). They are, however, less used in clinical practice.
The question remains open on whether 60 minutes after injection is the optimal timing for FDG PET/CT imaging. No optimal time has been defined in the literature. Uptake in breast tumors continues to increase beyond 60 minutes (6, 7) . Nevertheless, this time is widely used and has the advantage of simplicity.
is evolving. These past years, combined PET and computed tomography (CT) (PET/CT) systems have replaced PET alone in most nuclear medicine departments. The CT portion of PET/CT provides the anatomic information useful for accurate interpretation of PET signal. It also provides a map used for attenuation correction of PET images. It also palliates the low sensitivity of PET for very small pulmonary nodules. It is now widely accepted that the performance of FDG PET/CT is better than the performance of FDG PET alone in oncology, although the added value might differ according to the clinical situation (1) (2) (3) .
In this review, we examine the principles of this hybrid imaging approach, focusing on breast imaging. Then, we assess the advantages and limits of FDG PET/CT at diagnosis, initial staging, follow-up, and evaluation of response to therapy in breast cancer.
Principles of FDG PET/CT
Imaging usually starts 60 minutes after the intravenous injection of FDG. CT and PET data are acquired sequentially before being fused. The patient is instructed to avoid movement. Patients are imaged from the base of the skull to the midthigh, except for specific situations.
Imaging usually begins with the CT acquisition. Questions remain as to whether the CT part of PET/CT should be performed as contrast materialenhanced full-dose diagnostic CT or as nonenhanced, low-dose CT, with additional focused segmental examination in case of inconclusive findings. Some technical constraints imposed by the PET component, such as free breathing, might limit the full diagnostic power of CT when performed as part of PET/CT imaging. 18 F is a positron-emitting (b+) radionuclide. PET detects the dual-photons emitted in opposite directions following positron annihilation. The half-life of 18 F is 110 minutes. Most malignant breast tumors overexpress glucose transporters (especially glucose transporter 1 and glucose transporter 3) and show increased hexokinase activity (4, 5) . After being phosphorylated by the hexokinase, FDG does not continue 
Essentials
n Combined PET/CT is more sensitive and specific than either of its constituent imaging methods; it facilitates distinguishing normal physiologic uptake from pathologic FDG uptake, allows accurate localization of functional abnormalities, and reduces the incidence of false-positive and false-negative results of imaging studies.
n The factors that influence FDG uptake by breast tumors have an implication on how to interpret FDG PET/CT scans and who is the appropriate patient for imaging.
n FDG PET/CT is not part of current recommendations for initial staging in breast cancer patients; however, there is mounting evidence that, in high-risk patients, results of this examination may be used to modify staging and management in a substantial percentage of patients.
n On the basis of analysis of current literature, FDG PET/CT should be the first whole-body imaging modality used for restaging in breast cancer patients with known recurrence or those who are suspected of having recurrence.
n FDG PET/CT is emerging as a promising tool for early monitoring of the effectiveness of neoadjuvant chemotherapy; however, there are substantial disparities in regard to the way assessment of response is performed, with the need for standardization, and moreover, rules should be defined for each specific subtype of breast cancer (triple-negative breast cancer, HER2-overexpressing tumors, estrogen receptor-positive cancer).
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carcinoma) (12, 13) . Specificity can also be altered. Although rare, FDG uptake in some benign tumors, such as fibroadenomas, has been described (24) . High uptake is possible in inflammatory granulomatous mastitis (25) . The CT part of PET/CT has no additional value in this setting: It can eventually allow detection of a breast mass, but CT (especially nonenhanced CT) is In a study by Basu and colleagues (22) , tumors with a triple-negative phenotype had a higher FDG uptake.
Breast cancers with a p53 mutation were repeatedly shown to be associated with poorer patient outcome. A positive correlation between FDG uptake intensity and p53 status has been found in three studies (8, 11, 14) , but not in a fourth (9) .
We prospectively studied the relationship between tumor characteristics and the SUV in 132 women with breast tumors greater than 20 mm (median, 51 mm; range, 21-140 mm) (23) . It was clear that FDG uptake in the primary tumor correlated with several factors known to confer poorer prognosis. Thus, the uptake of FDG was, on average, twice as high for grade 3 tumors compared with grade 1 and 2 tumors (median maximum SUV [SUV max ], 9.7 vs 4.8; P , .0001) (Fig 1a) ; it was also higher for breast cancer with a p53 mutation. Estrogen receptor-negative tumors were more FDG-avid than estrogen receptor-positive tumors. Similarly, FDG uptake was higher in progesterone receptor-negative tumors than in progesterone receptor-positive tumors. Breast cancers with a triplenegative phenotype had a significantly higher SUV than did others (median SUV max , 9.2 vs 5.8; P = .0005) (Fig 1b) . Considering histologic tumor type, we confirmed lower tumoral uptake in 15 patients with invasive lobular carcinoma (median SUV max , 3.4) compared with the 107 patients with invasive ductal carcinoma (median SUV max , 6.6). We further showed that seven patients with metaplastic breast cancer, a less common variety, had a very high FDG uptake (median SUV max , 12.9) (23).
FDG PET/CT Has Little Role in Differentiating Benign from Malignant Breast Lesions
FDG PET imaging has poor sensitivity for infracentimetric tumors (sensitivity of ,50% in some studies) (13) . This is explained by the limited spatial resolution of PET and, in some cases, by tumor characteristics (eg, low FDG avidity in grade 1 cancer and/or in lobular What is most important within a given institution is to constantly adopt the same time delay after injection. The delay used at baseline imaging should be reproduced if the patient is referred for response evaluation. Some authors developed methods to make appropriate time corrections for tumor SUVs (6, 7) .
This pattern of dependence of SUV on the delay after injection has been well studied in untreated tumors (6,7), not for posttherapy measurement. Also, when clinicians perform SUV measurements for response evaluation, they should remember that there is a risk of underestimation of SUV values with PET instruments when the residual tumor is too small (partial volume effect). The time delay between the last chemotherapy use and FDG imaging might also influence response assessment.
FDG Uptake of Breast Cancer Depends on the Histologic and Biologic Characteristics of the Tumor
For a given tumor size, infiltrating ductal carcinoma has higher FDG uptake than infiltrating lobular carcinoma (4, (8) (9) (10) (11) (12) . The uptake in ductal carcinoma in situ is usually weak (8) .
FDG uptake intensity correlates with breast cancer grade (8, (13) (14) (15) (16) . There is also a correlation between the tumor proliferation index (Ki67 expression measured by using immunohistochemical analysis) and the intensity of FDG uptake (4, 8, 9, 15) .
There have been contradictory reports on steroid hormone receptor status and FDG uptake. Some studies showed no correlation between hormone receptor status and SUV values (9, 10, 13, 15, 17) . However, recent series with a large number of patients showed higher SUV in estrogen receptor-negative tumors (8, 14, (18) (19) (20) . Except for one study (21) , most authors have found no correlation between FDG uptake and HER2/neu expression (8, 9, 14, 15, 18) . Triple-negative breast tumors (negative for estrogen and progesterone receptors, and no HER2/neu overexpression) are currently a subject of major interest because of their aggressiveness, poor prognosis, and lack of targeted therapy. 
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Groheux et al sensitivity was 56% (range, 44%-67%) and mean specificity was 96% (range, 90%-99%) (33) . Diagnostic performance of PET/CT does not seem to be superior to that of ultrasonography (US) (16) or MR imaging (34) . PET/CT, therefore, cannot replace the sentinel node technique. Nevertheless, in a noninfectious setting, axillary node uptake is highly suggestive of malignancy, with a positive predictive value of more than 80% in most studies (32, 35) . Therefore, in the case of FDG uptake in the axilla, some authors recommend performing axillary clearance rather than sentinel node biopsy (32 
FDG PET/CT Comparison with Sentinel Node Biopsy for Axillary Staging
PET/CT cannot be used as a substitute for sentinel node biopsy in patients with early-stage breast cancer (30) . The spatial resolution of PET instruments precludes the detection of very small nodal metastases (31) . In the American prospective multicenter study published in 2004, FDG PET (without the CT component) was performed in 360 women with newly diagnosed invasive breast cancer (31) . For detecting axillary nodal metastasis, the mean sensitivity and specificity of PET were, respectively, 61% (range, 54%-67%) and 80% (range, 79%-81%) (31) . In a study by Veronesi et al (32) , in 236 patients with clinically negative findings for axillary involvement who underwent FDG PET prior to sentinel node biopsy, only 37% of patients with positive results of sentinel node biopsy had positive findings at PET. Overall accuracy and positive predictive value of FDG PET were, respectively, 70% and 88% (32) . In a recent meta-analysis (33) , researchers evaluated the diagnostic accuracy of PET (with or without CT). Across 19 studies of PET only (n = 1729), mean sensitivity was 66% (range, 50%-79%), and mean specificity was 93% (range, 89%-96%). Across seven studies of PET/CT (n = 862), mean unable to help define the nature (benign or malignant) of the mass.
To improve specificity, some authors would obtain a second series of PET images centered on the breast approximately 2 hours after FDG injection (dual-time imaging) (26, 27) . Indeed, FDG uptake seems to increase with time in the case of malignancy, while some inflammatory lesions show stable or decreasing uptake (26) . However, dual-time imaging is time consuming, and its usefulness has not yet been demonstrated in large series.
FDG PET/CT is not a substitute for biopsy in the positive diagnosis of breast cancer. However, when an unexpected focus of FDG uptake is detected in the breast during an FDG examination performed for other reasons, it is necessary to explore it with conventional imaging and possible biopsy because of the high risk of malignancy (28) . Among 4038 female patients undergoing FDG PET/CT for reasons other than breast cancer, unexpected FDG foci in the breast were identified in 33 patients (0.82%); 17 of these 33 foci proved to be malignant (28) .
Role of FDG PET/CT in Assessment of Multifocality and T Category of Breast Cancer
In only a few studies, the role of PET/CT to assess the T category was analyzed. This was because of the limited spatial resolution of PET; FDG imaging has less sensitivity and less accuracy than magnetic resonance (MR) imaging in the determination of the delineation of the primary tumor and in screening for multifocality (27) . Among 40 women undergoing PET/CT and MR imaging (27) , MR imaging aided classification of the T category correctly in 77% of cases and PET/CT aided classification in only 54% of cases (P = .001). Therefore, with conventional instruments, PET/CT currently does not have a role in the assessment of the size of the primary tumor and presence of multifocal disease.
Performance might improve with the advent of higher-resolution PET systems dedicated to breast imaging called positron emission mammography Detection of Lymph Node Involvement Outside Berg I and Berg II Levels PET/CT can be used to screen lymph nodes in the case of advanced tumor (Table 3) . Axillary clearance is usually Tumor Յ 2 cm in greatest dimension T2
Tumor . 2 cm but not . 5 cm in greatest dimension T3
Tumor . 5 cm in greatest dimension T4
Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or skin nodules) T4a
Extension to the chest wall, not including only pectoralis muscle adherence/invasion T4b
Ulceration and/or ipsilateral satellite nodules and/or edema (including peau d'orange) of the skin, which do not meet the criteria for inflammatory carcinoma T4c
Both T4a and T4b T4d
Inflammatory carcinoma Regional lymph nodes NX Regional lymph nodes cannot be assessed (eg, previously removed) N0
No regional lymph node metastasis N1
Metastases to movable ipsilateral level I and II axillary lymph nodes N2
Metastases in ipsilateral level I and II axillary lymph nodes that are clinically fixed or matted; or in clinically detected ipsilateral internal mammary nodes in the absence of clinically evident axillary lymph node metastases* N2a
Metastases in ipsilateral level I and II axillary lymph nodes fixed to one another (matted) or to other structures N2b
Metastases only in clinically detected ipsilateral internal mammary nodes and in the absence of clinically evident level I and II axillary lymph node metastases* N3 Metastases in ipsilateral infraclavicular (level III axillary) lymph nodes with or without level I and II axillary lymph node involvement; or in clinically detected ipsilateral internal mammary lymph nodes with clinically evident level I and II axillary lymph node metastases; or metastases in ipsilateral supraclavicular lymph nodes with or without axillary or internal mammary lymph node involvement* N3a
Metastases in ipsilateral infraclavicular lymph nodes N3b
Metastases in ipsilateral internal mammary lymph nodes and axillary lymph nodes N3c
Metastases in ipsilateral supraclavicular lymph nodes Distant metastasis M0 No distant metastasis M1 Distant metastasis
Note.-Adapted and reprinted, with permission, from reference 36.
* A clinically detected lymph node is defined as one detected by using imaging studies (excluding lymphoscintigraphy) or by using clinical examination and having characteristics highly suggestive of malignancy, or a presumed pathologic macrometastasis on the basis of results of fine-needle aspiration biopsy with cytologic examination. M0  T2  N0  M0  IIB  T2  N1  M0  T3  N0  M0  IIIA  T0  N2  M0  T1*  N2  M0  T2  N2  M0  T3  N1  M0  T3  N2  M0  IIIB  T4  N0  M0  T4  N1  M0  T4  N2  M0  IIIC  Any T  N3  M0 Note.-NA = not available, P = prospective study, R = retrospective study, WB = whole body .
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* Data are on a per-patient basis. † Unknown node metastases refer to the metastases to the extraaxillary nodes. ‡
The high percentage of modification in this study can be explained by the detection of axillary infiltrated nodes (17%), and in 12% of patients who were suspected of having metastases at conventional imaging, downstaging occurred on the basis of the PET findings. § Some metastases were also detected by using conventional imaging. (36) . In our preliminary study (40) of 39 patients with stages II-III breast carcinoma, PET/CT revealed three cases of extraaxillary lymph node involvement that were missed by using the conventional workup. In all three cases, the extent of the surgical clearance and/or of the radiation therapy fields was modified according to the PET/CT information. In another study, also encompassing patients with stages II-III breast carcinoma, radiation therapy was altered in seven patients with extraaxillary lymph node involvement (12% of the total group) missed by using US (41).
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Detection of Distant Metastases
Inflammatory breast cancer (T4d) is associated with a high rate of distant metastases, and PET/CT is useful for detecting occult metastases in these patients (25, 37, 38) . In the study by Alberini and colleagues (25) , PET/CT results suggested distant metastases in 18 of 59 patients with inflammatory breast cancer (31%), in only six of them, these metastases were recognized with a conventional workup. In patients who were not suspected of having distant metastases, distant metastases were also found in a nonnegligible percentage of patients with noninflammatory, but large (. 3 cm) breast cancer (39), as well as in two series of patients in whom PET/CT was used in the workup of patients with stage II or III breast cancer (40, 42) . Hybrid PET/CT imaging leads not only to upstaging but also sometimes to downstaging of cancer (39, 42) . In the study by Fuster et al (39) , additional PET findings led to downstaging of cancer in seven of 60 patients who were suspected of having metastatic disease suggested by using conventional imaging procedures: Seven lesions in bone scintigraphy images and no FDG uptake were finally confirmed to be benign.
Concerning bone lesions, many teams have found that, while PET is more efficient than CT or bone scintigraphy for depicting lytic or mixed bone metastases and bone marrow lesions, PET can lack sensitivity for evidencing purely sclerotic bone metastases (43, 44) . For this reason, some teams advise clinicians to perform bone 
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Groheux et al can reveal small nodules without FDG uptake. It should be noted that freebreathing CT is less efficient than standard diagnostic thoracic CT. Finally, the main limitation of PET/CT is its lack of sensitivity for brain metastases, because of physiologic FDG uptake in the brain.
In Which Patient Should FDG PET/CT Be Performed at Initial Staging?
The exact clinical stage at which PET/ CT could be performed with a favorable balanced cost-effectiveness is uncertain. In most studies, patients with stage II and stage III carcinoma were mixed (Table 3) . We recently reported the performance of diffusion-weighted MR imaging in the detection of bone metastases. However, more investigation on this topic is required. In the staging of locally advanced breast cancer, PET/CT can also reveal distant lymph nodes and visceral metastases. In a group of 41 patients with inflammatory breast cancer, PET/CT revealed mediastinal lymph node metastases in 24% and liver metastases in 15% (37) . In regard to the pulmonary parenchyma, PET efficiently depicts supracentimetric pulmonary nodules. However, because of the partial volume effect and respiratory movements, PET lacks sensitivity for smaller nodules. Careful scrutiny of the CT data obtained during the hybrid examination osteocondensation on the CT images so that they can be detected by using the hybrid PET/CT procedure (42) . In a retrospective study of 163 women, PET/CT and bone scintigraphy demonstrated a high degree of concordance, which suggested redundancy for detecting osseous metastases (46) . Results of this study suggested that PET/CT was more accurate than scintigraphy to depict bone metastases (46) . Consequently, the authors concluded that bone scanning may potentially be avoided in patients undergoing FDG PET/CT (46) . Figure 6 shows a bone metastasis evidenced by using FDG PET/CT in the staging of a large breast carcinoma. Results from a prospective study (47) showed that the performance of PET/CT was better than 
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results of standard staging studies are equivocal (49) .
Performance of PET/CT in Restaging of Breast Carcinoma
A patient may be suspected of having a breast cancer recurrence because of a clinical symptom, a radiologic finding, or an increase in a biological marker (cancer antigen 15-3 and/or carcinoembryonic antigen). In all these different settings, PET/CT seems to perform better than conventional imaging (wholebody CT and bone scanning for distant recurrences, US and mammography for local recurrences) and better than PET alone (50-59). Table 4 shows results of the main studies in which researchers evaluated the role of PET/CT. We excluded studies in which staging and restaging populations were mixed. However, even the listed studies have some limitations. Most of them were retrospective. PET/CT was sometimes compared with its own CT component without intravenous contrast material enhancement (Table 4) ; such CT scanning is obviously not state of the art. The sensitivity of FDG PET/CT ranged between 85% and 97%; the specificity, between 52% and 100%; and the accuracy, between 60% and 98% ( Table 4 ). The accuracy was particularly high (98%) in the study by Dirisamer and colleagues (55) . In this work, the CT component was performed with a diagnostic multidetector CT scanner, and 100 mL of contrast medium was routinely injected (55) .
Restaging by using PET/CT imaging results leads to a change in management in a substantial percentage of patients (51, 56, 57) . FDG PET/ CT has an important role in the setting of asymptomatic patients with rising tumor marker levels and negative conventional imaging results; this hybrid imaging allows detection of early recurrence, before conventional methods. The effect on a patient's outcome can be substantial. In the study by Grassetto and colleagues (57), 89 patients with breast cancer who had posttherapy rising tumor marker results from a prospective evaluation of the yield from FDG PET/CT in specific subsets of patients with stage IIA, IIB, and IIIA breast cancer (48 that the use of FDG PET/CT at initial staging of breast cancer patients might be appropriate starting with clinical stage IIB and primary operable stage IIIA (48) . Similar findings on a potential role of FDG PET/CT in stage IIB and primary operable stage IIIA cancers were also reported by Segaert and colleagues (42) . These results, if confirmed by findings in other series, might call for reevaluation of the National Comprehensive Cancer Network guidelines. These studies should also include an evaluation of the cost-effectiveness. At the time of writing this review, the National Comprehensive Cancer Network guidelines recommend FDG PET or FDG PET/CT in patients with inflammatory breast cancer (49) . They recommend against its use in stage IIB and primary operable stage IIIA breast carcinoma (T3N1 lesions) (49) . FDG PET/ CT is only advised in situations where
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Groheux et al Table 4 Studies Evaluating FDG PET/CT for Restaging Note.-CA 15-3 = carcinoma antigen 15-3, CE = contrast enhanced, CEA = carcinoembryonic antigen, NPV = negative predictive value, NA = not available , NE = nonenhanced, PPV = positive predictive value, WB = whole body.
* All studies were retrospective except that of Haug et al (52) , where it was not specified, and of Schmidt et al (54) , which was prospective.
Table 4 (continued)
Studies Evaluating FDG PET/CT for Restaging levels but negative conventional imaging (mammography, chest and abdomen contrast-enhanced CT, abdominal US, and bone scanning) results were examined with FDG PET/CT. Tumor deposits were detected in 40 of 89 patients, and 23 patients had a solitary small lesion treated by using radical therapy. In seven of these 23 patients, a complete disease remission lasting more than 1 year was observed. PET/CT is efficient for detecting a distant metastasis and to demonstrate local-regional relapses, especially in the chest wall, the axilla, and the extraaxillary lymph node basins (Fig 7) . Investigators in several studies have showed that PET/CT is more efficient than CT or MR imaging for depicting nodal recurrences (54) (55) (56) . In the study by Schmidt et al (54) , PET/CT was more sensitive than whole-body MR imaging to detect lymph node involvement (n = 21 vs n = 16); however, whole-body MR imaging was slightly more sensitive (n = 154 vs n = 147) in the detection of distant metastases. Recent data point to improved sensitivity of whole-body MR imaging when a diffusion-weighted sequence was added. Improvements are also expected with FDG PET/CT through the use of contrast enhancement for the CT part, respiratory gating, et cetera.
When a recurrence is depicted or a patient is suspected of having a recurrence by using conventional imaging, PET/CT is useful to determine whether this recurrence is isolated or not, and such a determination may have a potential effect on the patient's treatment. In a study of 56 patients who were clinically eligible for curative surgery of a local recurrence, PET/CT depicted additional lesions not visible at conventional imaging in 25 (45%) patients (56) .
Two meta-analyses have been recently published encompassing PET/ CT studies (60, 61) . In the first metaanalysis, MR imaging and PET (with or without CT) were more efficient than US or CT to detect recurrent breast cancer (61) . No difference was found between MR imaging and PET; unfortunately, PET and PET/CT were not separated in this analysis. In the second meta-analysis, PET and PET/CT modalities were
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separated (61) . Six studies performed with PET/CT were included (50) (51) (52) (53) (54) (55) . Hybrid PET/CT had significantly higher sensitivity compared with CT but the increase in specificity was not significant. PET/CT also had significantly higher sensitivity compared with PET, but the increase in specificity was not significant (61) . There were no significant differences in the sensitivity or specificity of PET/CT when compared with MR imaging, but only the study by Schmidt et al (54) was included.
In conclusion, FDG PET/CT is useful for detecting recurrence and for restaging in breast cancer patients (Figs 7-9 ).
Performance of PET/CT for Treatment Response Assessment
Early Evaluation of Neoadjuvant Chemotherapy with PET with or without CT Neoadjuvant chemotherapy (NAC) is the first treatment in nonoperable locally advanced and inflammatory breast cancer. NAC is also commonly used in case of operable but large tumor to increase the chances of performing breast-conserving surgery (62) . Although an overall survival benefit for NAC compared with adjuvant chemotherapy in operable breast cancer has not been clearly proved, it is generally accepted that absence of residual cancer cells in the primary tumor following NAC is strongly associated with improved disease-free survival and overall survival (63) . Pathologic complete response after completion of NAC occurs in 13%-26% of patients (62, 64) .
NAC is an excellent setting to document response of the tumor to the administered chemotherapy regimen which is not possible in the adjuvant setting. Early prediction during NAC of what would be the final pathologic response might offer an early opportunity to change strategy in case of ineffectiveness. Stopping ineffective chemotherapy could avoid unwarranted side effects. In several studies (65) (66) (67) (68) (69) (70) (71) (72) (73) (74) Second, the optimal timing for the interim PET remains unclear. For several teams, performing PET after the second course of NAC is a good compromise to evidence effects of chemotherapy and to still allow an early been proposed for discriminating metabolic responders (diminution of SUV superior to the threshold value) from nonresponders. The cutoff chosen is supposed to help best prediction of the final pathologic response. Unfortunately, the specific threshold value proposed varies dramatically across studies (Table  5) . Several factors can explain differences in the cutoff value (65) .
First, the definition of what is a good histopathologic responder varies. For example, Rousseau et al (68) define a tumor regression superior to 50% as a good response while SchwarzDose and colleagues (73) consider no residual invasive tumor or only a few which a possible role for metabolic evaluation with FDG PET and PET/CT was examined, investigators demonstrated a correlation between early changes in the SUV max value (after one or two courses of chemotherapy) and the final pathologic response at completion of chemotherapy (Fig 10) . Among these studies, only a few were performed with a PET/CT system (68, 71, 72, 74) (Table 5 ). In this setting, the CT part of the hybrid system is not decisive and the performance of the hybrid PET/CT system was no better than the performance of PET alone.
In every study, an optimal threshold value of decrease in SUV (DSUV) has Axial image shows that, after two courses of primary chemotherapy, SUV max was 2.3, corresponding to an 83% decrease (arrow). Mastectomy performed at completion of NAC (after eight courses) showed a pathologic complete response.
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Groheux et al Table 5 Studies Evaluating the Decrease of SUV Assessment of Response to Hormonal Therapy: The Paradoxical Metabolic Flare A paradoxical increase in FDG uptake during the 1st days after initiation of hormone therapy was observed in patients with a good therapeutic response. This phenomenon has been described with the term metabolic flare (86) . This effect typically occurs during the 10 days after initiation of hormone therapy (86) . An explanation for this phenomenon is that endocrine therapy has initial agonist effects before antagonist effects dominate. Therefore, an increase in SUV in tumors during PET performed early after the initiation of hormone therapy is predictive of a good therapeutic response (87) (88) (89) . However, these results have been reported in small numbers of patients, and furt work is therefore needed to better analyze this phenomenon.
Prognostic Value of FDG PET (/CT)
In the study by Inoue et al (90) , FDG PET was performed preoperatively in 81 women with breast cancer. Patients were dichotomized according to the SUV max into high-and low-SUV groups by using a cutoff value of an SUV max of 4.0 (90). The high-SUV group (n = 40) showed a significantly (P = .011) poorer prognosis than the low-SUV group (n = 41) (5-year disease-free survival rates, 75.0% vs 95.1%). Researchers in other studies have also suggested that the SUV in the primary tumor could be predictive of outcome (20, 25, 91, 92) . Unfortunately, the FDG uptake cutoff used to discriminate high from low uptake is different from one study to another. These findings are nevertheless in agreement with data showing higher change in tumor size can be assessed with anatomic imaging. Moreover, modification in bone metastases, pleural effusion, and lymphangitis, which are common sites of breast cancer dissemination, are difficult to assess.
Changes in metabolic activity generally occur earlier than changes in tumor size (Fig 9) . This is particularly the case for targeted therapies, because these treatments can render tumors metabolically inactive without substantial modification of their size. Functional imaging techniques such as PET can be used earlier than morphologic imaging methods to evaluate treatment response. Only a few studies reported on the clinical use of sequential FDG PET (with or without CT) in patients with metastatic breast disease. In most of them, PET is performed without CT (79) (80) (81) . Studies with PET/CT are clearly needed. There is some evidence that hybrid FDG PET/CT (when both CT information and tumor metabolic activity are considered) provides additional and useful information to assess the evaluation of systemic chemotherapy. For example, the increase in attenuation in bone metastases (measured in Hounsfield units) and the decrease in SUV are altogether potential predictors of response duration (82) (Fig 6) . Another important finding is that PET/ CT allows evaluation of response in many different metastases. Therefore, PET/CT is helpful to evidence a heterogeneous response (coexistence of responding and nonresponding lesions within the same patient) (83) .
Specific PET criteria for determining the therapeutic response have already been proposed by various working groups (84, 85) . For example, the experts of the European Organization for Research and Treatment of Cancer consider that reduction of more than 25% in the SUV within the tumor after several cycles of chemotherapy is classified as a partial metabolic response and an increase of at least 25% in the SUV, visible increase in the extent of FDG tumor uptake (20% in the longest dimension), or the appearance of new FDG uptake is progressive disease (84) . However, recommendations of the change of treatment in case of ineffectiveness (66, 68, 74) . However, performing response assessment as early as the first cycle might also be valuable (73) .
Furthermore, the pretreatment tumor SUV index must be high to detect a meaningful reduction during treatment (70, 73) . This requirement limits the use of iterative PET in case of tumors with a low SUV. It is important to note that low tumor metabolic activity at pretreatment could be an indicator of chemotherapeutic resistance (73) . In the study by Schwarz-Dose et al (73) , none of the 23 patients with initial SUV less than three achieved a complete histopathologic response.
On the other hand, breast cancer comprises different groups of tumors (estrogen receptor-positive tumors, tumors with HER2 overexpression, triple-negative tumors) with different response rates to chemotherapy, different risks of relapse, different treatment options, and different prognoses. We therefore suggest that the clinical aims of early FDG monitoring and the criteria used to assess effectiveness should be examined in specific subgroups (65, 75) . We recently reported results in the subset of patients with triple-negative tumors, showing that FDG PET/ CT at two cycles can be efficient in discriminating patients who are unlikely to achieve a complete pathologic response with the prescribed NAC regimen and have a high risk of early relapse (75) .
In total, encouraging data plea for a role of FDG PET (with or without CT) in the early evaluation of the response to NAC. However, more studies are necessary to better define criteria of evaluation. Moreover, the place of PET in comparison with MR imaging, which is also useful in the early evaluation of NAC, remains to be better determined (76) .
Evaluation of Response of Metastatic
Disease with FDG PET/CT Anatomic imaging, predominantly CT, is currently used to obtain measurements of tumor lesions before and after treatment for response assessment and follow-up (77, 78) . However, several cycles of treatment are needed before a SUV uptake in tumors of high histologic grade (grade 3) or in triple-negative tumors (Fig 1) .
FDG response of metastatic disease also has prognostic value. In a group of 47 patients, Cachin et al (93) showed that overall survival was significantly better for patients with negative findings on a PET scan after chemotherapy, in comparison with persistent FDG uptake (24 months vs 10 months, P , .001).
Conclusion
FDG PET/CT is very useful for restaging of cancer in patients with documented breast cancer recurrence or in those who are suspected of having breast cancer recurrence and is more efficient than PET alone and conventional imaging methods. FDG PET/CT is also efficient to perform the staging of locally advanced and inflammatory breast cancer. It allows detection of extraaxillary lymph nodes and distant metastases. PET/CT also brings valuable information in the staging of clinical stage IIB and primary operable stage IIIA breast carcinoma. In contrast, the spatial resolution of PET (approximately 5-6 mm) is not sufficient to allow the detection of early axillary node involvement and micrometastases. PET/CT cannot replace staging by using the sentinel node procedure. Also, PET is not recommended for the initial assessment of stage I breast cancer. The metabolic information provided by using PET has been shown to be valuable for the early assessment of response to chemotherapy (at the neoadjuvant and metastasis settings), but this indication remains to be validated.
